Stress protein GDF-15 predicts five-year death risk in emergency chest pain patients
In 4,779 chest pain patients, GDF-15 was a weak heart attack test but a strong predictor of 5-year mortality, outperforming troponin and NT-proBNP.
Résumé
Growth differentiation factor-15 (GDF-15) is a stress-responsive blood protein linked to heart disease and wasting. Researchers measured it in 4,779 adults who came to emergency departments with acute chest pain, alongside the standard heart markers troponin T and NT-proBNP. GDF-15 was only modestly useful for spotting heart attacks (AUC 0.69), so it won't replace troponin for diagnosis. Its strength was predicting death from any cause: C-index 0.86 at 90 days and 0.84 at five years. That matched troponin and NT-proBNP in the short term and beat them over five years. Adding GDF-15 to a model already containing age, sex, risk factors, kidney function, troponin and NT-proBNP still improved risk discrimination. The findings suggest GDF-15 works better as a mortality-risk marker than a heart-attack test.
Résumé détaillé
Chest pain is among the most common reasons for emergency visits, and clinicians have excellent tools for deciding who is having a heart attack. They are much less equipped to identify who among all chest pain patients, whatever the final diagnosis, faces a high long-term risk of death. GDF-15 is a stress-induced circulating cytokine already known to predict mortality after established myocardial infarction and implicated in cachexia, which makes it a candidate for that broader role.
This international multicenter study (APACE investigators) enrolled 4,779 unselected adults presenting to emergency departments with acute chest pain. Median age was 61 and 33.2% were women. GDF-15, high-sensitivity cardiac troponin T and NT-proBNP were measured at presentation. Final diagnoses were adjudicated: 17.9% had myocardial infarction, 20.8% other cardiac conditions and 61.3% non-cardiac disorders. Endpoints were Non-ST-elevation MI at presentation and all-cause death at 90 days and 5 years.
For diagnosing MI, GDF-15 performed only modestly (AUC 0.69). For prognosis it performed very well. The C-index for all-cause death was 0.86 (95% CI 0.82-0.90) at 90 days and 0.84 (0.82-0.85) at 5 years. This was comparable to hs-cTnT and NT-proBNP at 90 days and higher at 5 years. Over follow-up, 557 deaths (12.1%) occurred. GDF-15 also added meaningful discrimination on top of a base model with age, sex, cardiovascular risk factors, creatinine, hs-cTnT and NT-proBNP.
The results suggest GDF-15 is better understood as a marker of overall biological vulnerability than of acute coronary injury. It could help flag patients who merit closer follow-up or more aggressive risk-factor management, whatever their chest pain diagnosis.
Caveats: only the abstract was available, so effect sizes for incremental value, calibration and cause-specific mortality are not reported here. The design is observational, and the findings show prediction, not that lowering GDF-15 improves outcomes. Several authors report industry ties, including diagnostic companies.
Principales conclusions
- GDF-15 had only modest accuracy for diagnosing Non-ST-elevation MI at presentation (AUC 0.69), so it is not a substitute for troponin.
- GDF-15 predicted all-cause death very well at 90 days (C-index 0.86, 95% CI 0.82-0.90).
- At 5 years, GDF-15 reached a C-index of 0.84 (95% CI 0.82-0.85), higher than hs-cTnT and NT-proBNP.
- GDF-15 added meaningful prognostic discrimination beyond a base model including age, sex, risk factors, creatinine, hs-cTnT and NT-proBNP.
- Of 4,779 patients, 17.9% had MI and 61.3% had non-cardiac disorders, yet GDF-15 still stratified mortality risk.
Méthodologie
International multicenter diagnostic and prognostic cohort study (APACE) of 4,779 unselected emergency department patients with acute chest pain. GDF-15, hs-cTnT and NT-proBNP were measured at presentation, with final diagnoses adjudicated. Discrimination (AUC, C-index) was assessed for MI at presentation and for all-cause death at 90 days and 5 years, including incremental value over a rich base model.
Limites de l'étude
This analysis is based on the abstract only, so incremental value metrics, calibration and cause-specific mortality are not available. The observational design shows prediction, not causation, and GDF-15 is elevated in many non-cardiac conditions, so it is nonspecific. Several authors disclose industry funding, including from diagnostic manufacturers, and external validation and clinical utility trials are still needed.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :
